Drops petrosian n 1b (2b-7b their variants) for the treatment of allergic and diatopically diseases of the eyes and nose

 

(57) Abstract:

The invention relates to medicine, for treatment of allergic and diatopically diseases of the eyes and nose. Drops Petrosian 1B include kromolin or nedocromil sodium or cromoglicic acid, dexamethasone-21-phosphate sodium salt, boric acid and sterile buffer solution. Drops Petrosian 3B include instead of dexamethasone-21-phosphate sodium salt, diphenhydramine, and drops Petrosian 7 B - ephedrine hydrochloride. Advantages of the proposed compositions are higher efficiency, antibacterial and antifungal activity, lower side effects. These drops apply 1-2 drops in both halves of the nose and/or in both eyes 4-5 times a day. The use of drops has fewer contraindications, can cause short-term pain. 3 S. and 4 C.p. f-crystals.

The invention relates to medicine, in particular to the treatment of allergic and diatopically diseases of the eyes and nose.

Known traditional separate application of antihistamines, sympathomimetics, corticosteroids for treatment of allergic and diatopically diseases of the eyes and nose [1]. To ensure also used simple and complex composition is tion drops "Deksona" for the eyes and Sofradex" for the eyes, nose and ears [3]. Successfully apply the nose drops, consisting of prednisolone 0,05, ephedrine hydrochloride 0,1, Dimedrol 0,05, novocaine solution of 0.5% - 10 ml [4].

The disadvantages of these drugs are no profilaktirujut immunological mechanism of action, warning the emergence and development of allergic and diatopically diseases of the eyes and nose, low efficiency in the treatment of these diseases.

The most similar content offered drops are drops for the eyes and/or nose, containing any drug interoperably group of substances that differ from each other equivalent signs and have shared significant technical equivalent sign inflamatornog immunological mechanism of inhibition of degranulation mastocytes (fat cells) and the allocation of these inflammatory mediators. These include drops "Bromohexyl" containing cromoglicic acid 2% [5], spray for intranasal use "Tiled" containing nedocromil sodium, eye drops and nose "Lamusa" containing kromolin sodium (disodium cromoglycate) 2% [6]. The proposed solution will improve all three similar, any of which may be selected for PR is apply for the eyes and nose "Iteral", consisting of the following components, wt.%/about.

Kromolin sodium - 2

The benzalkonium chloride is 0.01

(as preservative)

Sterile buffer solution - as required [7]

The disadvantages of this drug is that it does not possess anti-allergic, anti-inflammatory and antiseptic action, not pain acute manifestations of allergic and diatopically diseases of the eyes and the nose in particular is complicated by microbial and/or fungal infection, but only to some extent warns them. The effect of the application drops "Iteral" minor, develops slowly, reaching a maximum within 2-4 weeks of starting treatment, this increases the incidence of idiosyncrasy to the drug.

The aim of the present invention is to eliminate the above drawbacks and increase the efficiency of the drops in the treatment of allergic and diatopically diseases of the eyes and nose, in particular, is complicated by microbial and/or fungal infection by adding drops of new properties, allowing multi-dimensional impact on the disease, arising from anti-allergic, anti-inflammatory, mestnoanesteziruyuschee, desensibiliziruyuschimi in combination with immunological mechanism for the prevention of disease, and increase effectiveness by obtaining direct synergistic and potentiating properties in the inventive compositions, a significant decrease in the number and severity of toxic and side effects, obtain new properties, allowing to arrest the acute manifestations of the disease.

These goals are achieved by the fact that the drops for the treatment of allergic and diatopically diseases of the eyes and nose, containing kromolin sodium, a drug that has the technical equivalent sign interoperably group of substances, namely immunological mechanism of inhibition of degranulation mastocytes and allocation of these mediators of inflammation, providing profilaktirujut impact on the disease, also include in various embodiments, the dexamethasone-21-phosphate sodium salt, has anti-inflammatory, desensitizing and anti-allergic effects, diphenhydramine (diphenhydramine hydrochloride), providing antihistamines, mestnoanesteziruyuschee decongestants and reducing the permeability of the capillary action of ephedrine hydrochloride, calling vasoconstrictor and decongestant effects, boric acid provides antiseptic action. The direct consequence is comprised of a significant increase in the effectiveness of drops, the possibility of multi-faceted impact on the disease. The use of these drugs in the inventive compositions drops gives a qualitatively new healing properties, helps to arrest the acute manifestations of the disease, antiseptic, reduces swelling and inflammation of the mucous membranes, which dramatically reduces the amount of discharge from eyes and nose, make contact inflamatornog ingredient with mucous, which increases the efficiency of its action. In turn interoperable profilaktirujut effect on the mucous increases the efficiency of the accompanying ingredients. This interaction leads to a rapid regression of the disease, can significantly reduce, in comparison with traditionally used used dosages of the components of the compositions. The use of lower dosages of the drugs, while maintaining a more pronounced action drops, explains the significant reduction of toxic and side effects. The presence of some of the compositions Dimedrol and/or dexamethasone-21-phosphate can prevent the occurrence of idiosyncrasy to intopathname component compositions. This is accomplished in seven cases drops. In the proposed composition N 1B and the sludge sodium, or cromoglicate acid - 0.5 - 4

Dexamethasone-21-phosphate sodium salt - 0,05 - 0,1

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with desensitizing, anti-inflammatory and anti-allergic action of dexamethasone-21-phosphate and antiseptic boric acid. Drops are more effective new therapeutic properties antiseptic, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, to reduce the swelling and inflammation of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 2B ingredients used in the composition in weight. %/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0.5 - 4

Dexamethasone-21-phosphate sodium salt - 0,05 - 0,1

Ephedrine hydrochloride - 1 - 5

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

the basis of action which lies interoperably immunologic Amazon-21-phosphate, as well as vasoconstrictor and anti-inflammatory effect of ephedrine hydrochloride in combination with antiseptic boric acid. Drops are more effective than the prototype and drops N 1B, new therapeutic properties antiseptic, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, to reduce the swelling and inflammation of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 3B ingredients used in the composition in weight. %/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0.5 - 4

Diphenhydramine - 0,1 - 0,5

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with antihistamines, mestnoanesteziruushim, anti-inflammatory and reduces capillary permeability effect of dimetrota and antiseptic boric acid. Drops are more effective new therapeutic properties antiseptic, direct synergetics is their acute manifestations of the disease, to reduce swelling and inflammation, soreness and sensitivity of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 3B ingredients used in the composition in weight. %/volume:

Kromolin sodium or nedocromil sodium, or cromoglicic acid - 0.5 - 4

Diphenhydramine - 0,1 - 0,5

Dexamethasone-21-phosphate sodium salt - 0,05 - 0,1

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with antihistamines, mestnoanesteziruushim, anti-inflammatory and reduces capillary permeability effect Dimedrol, as well as desensitizing, anti-inflammatory and anti-allergic action of dexamethasone-21-phosphate in combination with antiseptic boric acid. Drops are more effective than the prototype and drops N 1B and N 3B, new therapeutic properties antiseptic, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation, pain is kromolin sodium.

In the song drops N 5B ingredients used in the composition in weight. %/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0.5 - 4

Diphenhydramine - 0,1 - 0,5

Ephedrine hydrochloride - 1 - 5

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with antihistamines, mestnoanesteziruushim, anti-inflammatory and reduces capillary permeability effect Dimedrol, as well as with vasoconstrictors, anti-edematous action of ephedrine hydrochloride in combination with antiseptic boric acid. Drops are more effective than the prototype and drops N 3B, new therapeutic properties antiseptic, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation, pain and sensitivity of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 6B ingredients used in the composition in weight. %/volume:

Kromolin sodium, rieva Sol - 0,05 - 0,1

Ephedrine hydrochloride - 1 - 5

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

the basis of action which lies interoperably immunological mechanism in combination with antihistamines, mestnoanesteziruushim, anti-inflammatory and reduces capillary permeability effect Dimedrol, as well as desensitizing, anti-inflammatory and anti-allergic action of dexamethasone-21-phosphate, with vasoconstrictor and anti-inflammatory effect of ephedrine hydrochloride, as well as with antiseptic boric acid. Drops are more effective than the prototype and drops N 1B - N 5B and N 7B, new therapeutic properties antiseptic, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation, pain and sensitivity of the mucous membranes, the amount of discharge from eyes and nose, to prevent the development of idiosyncrasy to kromolin sodium.

In the song drops N 7B ingredients used in the composition in weight. %/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0.5 - 4

the basis of action which lies interoperably immunological mechanism in combination with vasoconstrictor and anti-inflammatory effect of ephedrine hydrochloride and antiseptic boric acid. Drops are more effective than the prototype, new therapeutic properties antiseptic, direct and synergistic article concludes that the effects of lower toxicity and side effects, the ability to arrest the acute manifestations of the disease, reduce swelling, inflammation of the mucous membranes, the amount of discharge from eyes and nose.

The analysis claimed the compositions reveals that this invention improved three similar: kromolin sodium, nedocromil sodium and cromoglicate acid, each of which can be the prototype.

Compositions differ from the prototype with additional ingredients, namely, dexamethasone-21-phosphate, Dimedrol, ephedrine hydrochloride and boric acid. Thus the claimed invention meets the criterion of "novelty."

Analysis of the known preparations and compositions of the drops used to treat allergic and diatopically diseases of the eyes and nose, showed that all input is of waist, they are in the present decision and the absence of any of them in essential features is not possible to obtain a positive effect. The inventive solution is characterized by a new set of essential features and meets the criterion of "substantial differences".

Direct and synergistic article concludes that effects, when using lower than srednestatisticheskiy, dosages of ingredients, the higher the efficiency of the drops, and treatment efficacy, reduce toxicity and side effects from the use of drops, improving contact kromolin sodium with mucous due to a sharp reduce swelling and inflammation of the mucous membranes, as well as reducing the number of discharge from eyes and nose, properties, allowing to arrest the acute manifestations of the disease, including forms, complicated by infection, gives grounds to conclude that under the proposed solutions to the criterion of "inventive step".

Advantages of the proposed compositions for the treatment of allergic and diatopically diseases of the eyes and nose, in comparison with analogues are significantly higher efficiency, decreasing execessively long their application, use drops when complicated by bacterial and/or fungal infection diseases of the eyes and nose. The variety of compositions allows the main requirement for the treatment of allergic and diatopically diseases of the eyes and nose, namely the alternation of species drops every 5-7 days because of the possible development of the idiosyncrasies of the individual ingredients, as well as to prevent the development of side effects, such as tahifilaksii phenomenon or reduce the vasoconstrictive effect of sympathomimetics on the 5-7th day of their application, and also facilitates the choice of drops including contraindications. Drops are used for a new purpose not only as profilaktirujut funds, but also for relief of acute manifestations of disease, including complications of bacterial and/or fungal infection. The use of drops does not require prior use of other drugs that restore the patency of the nasal passages. The choice of quantitative and qualitative ratio of components is based on the basis of sex, age, presence of contraindications. As example 1 shows the most frequently used by the author of the compounds in the following ratio of ingredients:
rieva Sol - 0,05

Boric acid - 1,5

Sterile buffer solution To 100.0 ml

N 2B Kromolin sodium or nedocromil sodium, or cromoglicate acid - 1,0

Dexamethasone-21-phosphate sodium salt - 0,05

Ephedrine hydrochloride - 1,0

Boric acid - 1,5

Sterile buffer solution To 100.0 ml

N 3B Kromolin sodium or nedocromil sodium, or cromoglicate acid - 1,0

Diphenhydramine - 0,3

Boric acid - 1,5

Sterile buffer solution To 100.0 ml

N 4B Kromolin sodium or nedocromil sodium, or cromoglicate acid - 1,0

Diphenhydramine - 0,2

Dexamethasone-21-phosphate sodium salt - 0,05

Boric acid - 1,5

Sterile buffer solution To 100.0 ml

N 5B Kromolin sodium or nedocromil sodium, or cromoglicate acid - 1,0

Diphenhydramine - 0,2

Ephedrine hydrochloride - 1,0

Boric acid - 1,5

Sterile buffer solution To 100.0 ml

N 6B Kromolin sodium or nedocromil sodium, or cromoglicate acid - 1,0

Diphenhydramine - 0,2

Dexamethasone-21-phosphate sodium salt - 0,05

Ephedrine hydrochloride - 1,0

Boric acid - 1,5

Sterile buffer solution To 100.0 ml

N 7B Kromolin sodium or nedocromil sodium, or cromoglicate Ki

Proposed drops were used by the author for 6 years, often as the only tool in the treatment of allergic and diatopically diseases of the eyes and nose, in particular, complicated by bacterial and/or fungal infection. The majority of patients noted improvement in health, 21% of patients remission for up to 6 months. The use of drops showed high efficiency for urgent conditions in patients with allergic and autopicking diseases of the eyes and nose, allergic angioedema in the eyes and nose.

All of these songs drops apply 1-2 drops for digging into both halves of the nose and(or) in both eyes 4-5 times a day at equal intervals of time - 4-5 hours it is Recommended that the alternation of the form of droplets in 7-10 days.

The use of drops Petrosian N 1B contraindications intolerance to any ingredient. With long-term use drops some patients may experience increased intraocular pressure. Caution should be exercised when prescribing for children up to 5 years and pregnant women.

The use of drops Petrosian N 3B contraindications intolerance to any ingredient, requires caution in children atonicheskoy disease, atherosclerosis, intolerance to any ingredient. Used with caution in chronic diseases of the myocardium, ray and in the elderly. Caution should be exercised when prescribing for children up to 5 years and pregnant women.

The use of drops Petrosian N 2-N 4B, N 6B is contraindicated in hypertension, atherosclerosis, intolerance to any ingredient. With long-term use drops some patients may experience increased intraocular pressure. Used with caution in chronic diseases of the myocardium, hyperthyroidism, the elderly, children under 5 and pregnant.

Sources of information

1. C. I. Picky, N. In. Adrianova, A. C. Artamonova. Allergic diseases. - M.: Medicine, 1991. (p. 194 p. 205)

2. M. D. Mashkovsky. Medicinal product. - Vilnius, 1994.

3. N. B. Nikolaev, B. R. Alperovitch, C. N. Sazanov, E. C. Shih. On The Main Page. Drugs of foreign firms in Russia. ): Astra Pharm Service, 1995.

4. I. S. Chekman, A. I. Gritsyuk, C. I. Grishchenko. Prescription reference of the doctor. - Kiev, 1985.

5. C. E. Romanovsky. New drugs in pharmacies Russia. Rostov-on-don, Phoenix, 1996, page 321. M: the Medical center under the government of the Russian Federation, 1994, page 113.

7. Instruction on the use of eye drops "Iteral", 1994 (prototype).

1. Drops for treatment of allergic and diatopically diseases of the eyes and nose containing sterile buffer solution, characterized in that they additionally contain kromolin sodium or nedocromil sodium or cromoglicic acid, dexamethasone-21-hospitallevel salt and boric acid in the following ratio, wt.%/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0.5 - 4

Dexamethasone-21-phosphate sodium salt - 0,05 - 0,1

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

2. Drops under item 1, characterized in that it further contain ephedrine hydrochloride in the amount of 1 - 5 wt.%/volume.

3. Drops for treatment of allergic and diatopically diseases of the eyes and nose containing sterile buffer solution, characterized in that they additionally contain kromolin sodium or nedocromil sodium or cromoglicic acid, diphenhydramine and boric acid in the following ratio, wt. %/volume:

Kromolin sodium or nedocromil sodium, or kroe - As you want

4. Drops on p. 3, characterized in that it further contains dexamethasone-21-phosphate sodium salt in a quantity of 0.05 - 0.1 wt.%/volume.

5. Drops on p. 3, characterized in that it further contain ephedrine hydrochloride in the amount of 1 - 5 wt.%/volume.

6. Drops on p. 3, characterized in that it further contains dexamethasone-21-phosphate sodium salt in a quantity of 0.05 - 0.1 all.%/volume and ephedrine hydrochloride in the amount of 1 - 5 wt.%/volume.

7. Drops for treatment of allergic and diatopically diseases of the eyes and nose containing sterile buffer solution, characterized in that they additionally contain kromolin sodium or nedocromil sodium, or cromoglicate acid ephedrine hydrochloride and boric acid in the following ratio, wt.%/volume:

Kromolin sodium or nedocromil sodium, or cromoglicate acid - 0.5 - 4

Ephedrine hydrochloride - 1 - 5

Boric acid - 1,0 - 2,0

Sterile buffer solution - as required

 

Same patents:
The invention relates to medicine, for treatment of allergic and diatopically diseases of the eyes and nose
The invention relates to medicine, in particular to the means, possessing tonic and tonic effect, and can be used for General strengthening of the body, as well as for treatment of the gastrointestinal tract, upper respiratory tract, strengthen the cardiovascular system

The invention relates to medicine and relates to a method of obtaining herbal substances with adaptogenic activity

The invention relates to pharmaceutical industry and relates to biologically active agents derived from plant materials

The invention relates to medicine and for the preparation for the local treatment of superficial changes on the skin and mucous membranes, as well as for the treatment of infections of the skin and mucous membranes on the basis of the reaction of interaction between the solution of 1 - 5.5 M nitric acid with 45 - 170 mmol of primary C1- C5-alkanol on 1 l of nitric acid, as well as the way to obtain the drug

The invention relates to pharmaceutical technology and relates to a new pharmaceutical composition with analgesic activity
The invention relates to pharmaceutical industry, and in particular to improving technologies for injection K(Na) salt of benzylpenicillin (BP), which is used in medicine to treat diseases caused by gram-positive organisms and gram-negative cocci, and for the manufacture of various dosage forms based on it, such as: benzylpenicillin procaine salt, economically-1, bicillin-1, bicillin-3, bicillin-5, spectrum of antimicrobial action of which is similar to the spectrum of benzylpenicillin

The invention relates to new peptides with organizaitnal activity with high biological activity of the same type as the natural compound HRV, but with a shorter amino acid chain
The invention relates to medicine, namely to ophthalmology, and can be used to replace the moisture of the anterior chamber, and washing the anterior chamber of the eye and other tissues of the eye during surgery
The invention relates to medicine, for treatment of allergic and diatopically diseases of the eyes and nose

The invention relates to tetraethylammonium compounds of the formula I

< / BR>
and their pharmaceutically acceptable salts,

where R1represents one or more substituents selected from H, halogen, hydroxy, alkyl with 1 to 3 carbon atoms (optionally substituted by hydroxyl), alkoxyl with 1 to 3 carbon atoms, alkylthio with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, nitro, cyano, Polygalaceae with 1 to 3 carbon atoms, polyalkyloxy with 1 to 3 carbon atoms, phenyl (optionally substituted by one or more substituents selected from halogen, alkyl with 1 to 3 carbon atoms, alkoxy with 1 to 3 carbon atoms), or R1is carbamoyl, optional alkilirovanny one or two alkyl groups, each independently from 1 to 3 carbon atoms;

R2represents an aliphatic group containing 1 to 3 carbon atoms, optionally substituted by hydroxy or alkoxy containing 1 to 3 carbon atoms;

E represents alkylenes chain containing 2 to 5 carbon atoms, optionally substituted by one or more alkyl groups containing 1 to 3 atom is dinasovymi or different and are independently an alkyl of 1 3 carbon atoms, alkoxy with 1 to 3 carbon atoms, halogen, hydroxy, polyaluminum with 1 to 3 carbon atoms, polyalkyloxy with 1 to 3 carbon atoms, cyano, alkylthio with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, alkylsulfonyl with 1 to 3 carbon atoms, phenyl (optionally substituted by one or more substituents selected from halogen, alkyl with 1 to 3 carbon atoms or alkoxy with 1 to 3 carbon atoms), carbamoyl, optional alkilirovanny one or two alkyl groups, each of which is independently from 1 to 3 carbon atoms, or G represents a phenyl ring having condensed with him heterocyclic or aromatic carbocyclic ring,

and O-acylated derivatives
The invention relates to medicine, Nephrology

The invention relates to 6-[X-(2-hydroxyethyl)aminoalkyl]-5,11-dioxo-5,6,-dihydro-11H - indeno[1,2-C]isoquinolines of the General formula I

< / BR>
in which

X represents the number of carbon atoms equal to 0-5 in aminoalkyl group, located at the nitrogen atom in the 6 position of the canonical formulas indrosophila, to their salts with inorganic and organic acids and method of production thereof

The invention relates to water-soluble derivative of camptothecin described by formula (I)

< / BR>
where n = 1 or 2; 1) R1and R2taken separately, represent hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy lower alkyl; 2) R1represents hydrogen, lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl or lower alkoxy lower alkyl; R2is-COR3where R3represents hydrogen, lower alkyl, pergola-lower alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl, lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy, lower alkoxy lower alkyl; 3) R1and R2taken together with the connecting nitrogen atom form a saturated 3-7-atom heterocyclic group of formula 1A

< / BR>
where Y represents O, S, CH2, NR4where R4represents hydrogen, lower alkyl, pergola-lower alkyl, aryl, aryl substituted by one or more substituents selected from the group comprising lower alkyloxy lower alkyl, or COR5where R5represents hydrogen, lower alkyl, pergola-lower alkyl, lower alkoxy, aryl, aryl substituted by one or more substituents selected from the group comprising lower alkyl, pergola-lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl; and their pharmaceutically acceptable salts, their use for the treatment of tumors and methods of preparation

The invention relates to new chemical substances possessing valuable properties, in particular derivatives pyridyl General formula (I)

< / BR>
where

n is the number 2, 3, 4 or 5,

A - uglerodsesola communication or unbranched Allenova group with 1 to 4 carbon atoms, unsubstituted or substituted by one or two alkyl groups,

X - nitromethylene group, cyanomethylene group, unsubstituted or substituted by a residue R6with the following for R4values except tetrazole, or a group of formula =N-R7where R7is cyano, alkanesulfonyl group, phenylsulfonyl group, phenylalkylamine group, aminosulfonyl group, alkylaminocarbonyl group, dialkylaminoalkyl group, phenylcarbonylamino group, aminocarbonyl group, alkylaminocarbonyl group or dialkylaminoalkyl group,

Y - alkoxygroup, fenoxaprop, allylthiourea, phenylthiourea or a group of the formula-R8NR9where R8means a hydrogen atom, an unbranched or branched alkyl group with 1 to 10 carbon atoms, which is in the 2nd, 3rd or 4th position can be C is POI or peredelnoj group, alkyl group with 1 to 4 carbon atoms, which may optionally be substituted with hydroxyl group in the 2 nd, 3rd or 4th position, cycloalkyl group with 3 or 4 carbon atoms, cycloalkyl group with 5-8 carbon atoms, in which one ethylene bridge can be replaced on-phenylenebis group, bicycloalkyl group with 6 to 8 carbon atoms, unsubstituted or substituted 1, 2 or 3 alkyl groups, adamantly group, alkoxygroup or trimethylsilylethynyl group, and R9is a hydrogen atom or an unbranched alkyl group, or R8and R9together with in between the nitrogen atoms form an unsubstituted or substituted by one or two alkyl groups or phenyl group, cyclic alkalinising with 4 to 6 carbon atoms, in which one ethylene bridge in the provisions of 3.4 can be replaced on-phenylenebis group, morpholinopropan or piperazinone, unsubstituted or substituted in the 4-position of the alkyl group with 1 to 3 carbon atoms or phenyl group,

R1is a hydrogen atom or an alkyl group with 1 to 3 carbon atoms,

R2and R3is a hydrogen atom or together form a carbon-carbon bond,

Pyr - Peregrina group, unsubstituted or sameena the group, alkylaminocarbonyl group, dialkylaminoalkyl group, group, translated in vivo metabolic by carboxyl group or carboxyl group, if Y represents the group R8NR9where R8and R9have the above meaning,

R5is a hydrogen atom or the halogen, alkyl, alkoxy or trifluoromethyl,

all of the aforementioned alkyl and CNS remains, if nothing else is mentioned, have 1 to 3 carbon atoms, and, if nothing else is mentioned, all the above-mentioned phenyl nuclei may be mono - or tizamidine identical or different substituents from the group comprising an atom of fluorine, chlorine, or bromine, alkyl, hydroxyl, alkoxyl, carboxyl, phenyl, nitro-, amino-, alkylamino, dialkylamino, alkanolamine, cyano, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminoalkyl, trifluoromethyl, alkanoyl, aminosulfonyl, alkylaminocarbonyl and dialkylaminoalkyl,< / BR>
their enantiomers, CIS - or TRANS-isomers, if R2and R3together denote a carbon-carbon bond, and their salts

The invention relates to the derivatives of decahydroquinoline formula active receptor antagonist amino acid-mediated excitation, which can find application in medicine, and to pharmaceutical compositions based on them
The invention relates to medicine, for treatment of allergic and diatopically diseases of the eyes and nose
Up!